Azitra Inc. Announces Promising Safety Results for ATR-12 Phase 1b Clinical Trial in Netherton Syndrome and Initiates ATR-04 Phase 1/2 Trial for EGFRi-Associated Dermal Toxicity

Reuters09-04

<a href="https://laohu8.com/S/AZTR">Azitra Inc</a>. Announces Promising Safety Results for ATR-12 Phase 1b Clinical Trial in Netherton Syndrome and Initiates ATR-04 Phase 1/2 Trial for EGFRi-Associated Dermal Toxicity

Azitra, Inc., a clinical stage biopharmaceutical company specializing in precision dermatology, has announced new developments in its clinical trials pipeline. The company recently reported promising safety results from its Phase 1b clinical trial of the ATR-12 program for Netherton syndrome. Additionally, Azitra has initiated a Phase 1/2 clinical trial for the ATR-04 program, targeting EGFR inhibitor-associated dermal toxicity in adults. The design of the ATR-04 trial was previously presented at the 2025 American Society of Clinical Oncology Annual Meeting. Further updates and progress on these programs will be presented by Cofounder and Chief Operating Officer, Travis Whitfill, Ph.D., MPH, during a virtual presentation at the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY64956) on September 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2564637487?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564637487","market":"us","top_or_hot":-1,"title":"Azitra Inc. Announces Promising Safety Results for ATR-12 Phase 1b Clinical Trial in Netherton Syndrome and Initiates ATR-04 Phase 1/2 Trial for EGFRi-Associated Dermal Toxicity","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AZTR\">Azitra Inc</a>. Announces Promising Safety Results for ATR-12 Phase 1b Clinical Trial in Netherton Syndrome and Initiates ATR-04 Phase 1/2 Trial for EGFRi-Associated Dermal Toxicity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Azitra, Inc., a clinical stage biopharmaceutical company specializing in precision dermatology, has announced new developments in its clinical trials pipeline. The company recently reported promising safety results from its Phase 1b clinical trial of the ATR-12 program for Netherton syndrome. Additionally, Azitra has initiated a Phase 1/2 clinical trial for the ATR-04 program, targeting EGFR inhibitor-associated dermal toxicity in adults. The design of the ATR-04 trial was previously presented at the 2025 American Society of Clinical Oncology Annual Meeting. Further updates and progress on these programs will be presented by Cofounder and Chief Operating Officer, Travis Whitfill, Ph.D., MPH, during a virtual presentation at the upcoming H.C. Wainwright 27th Annual Global Investment Conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY64956) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Azitra Inc. Announces Promising Safety Results for ATR-12 Phase 1b Clinical Trial in Netherton Syndrome and Initiates ATR-04 Phase 1/2 Trial for EGFRi-Associated Dermal Toxicity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAzitra Inc. Announces Promising Safety Results for ATR-12 Phase 1b Clinical Trial in Netherton Syndrome and Initiates ATR-04 Phase 1/2 Trial for EGFRi-Associated Dermal Toxicity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 20:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AZTR\">Azitra Inc</a>. Announces Promising Safety Results for ATR-12 Phase 1b Clinical Trial in Netherton Syndrome and Initiates ATR-04 Phase 1/2 Trial for EGFRi-Associated Dermal Toxicity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Azitra, Inc., a clinical stage biopharmaceutical company specializing in precision dermatology, has announced new developments in its clinical trials pipeline. The company recently reported promising safety results from its Phase 1b clinical trial of the ATR-12 program for Netherton syndrome. Additionally, Azitra has initiated a Phase 1/2 clinical trial for the ATR-04 program, targeting EGFR inhibitor-associated dermal toxicity in adults. The design of the ATR-04 trial was previously presented at the 2025 American Society of Clinical Oncology Annual Meeting. Further updates and progress on these programs will be presented by Cofounder and Chief Operating Officer, Travis Whitfill, Ph.D., MPH, during a virtual presentation at the upcoming H.C. Wainwright 27th Annual Global Investment Conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY64956) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDLbjv4Xj:1","article_id":"2564637487","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564637487","pubTimestamp":1756987866,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Azitra Inc. Announces Promising Safety Results for ATR-12 Phase 1b Clinical Trial in Netherton Syndrome and Initiates ATR-04 Phase 1/2 Trial for EGFRi-Associated Dermal Toxicity. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire  on September 04, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AZTR":"Azitra Inc"},"translate_title":"Azitra Inc.宣布ATR-12治疗Netherton综合征的1b期临床试验具有良好的安全性结果，并启动ATR-04治疗EGFRi相关皮肤毒性的1/2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZTR":0.9},"content_text":"Azitra Inc. Announces Promising Safety Results for ATR-12 Phase 1b Clinical Trial in Netherton Syndrome and Initiates ATR-04 Phase 1/2 Trial for EGFRi-Associated Dermal Toxicity\n    \n\n        Azitra, Inc., a clinical stage biopharmaceutical company specializing in precision dermatology, has announced new developments in its clinical trials pipeline. The company recently reported promising safety results from its Phase 1b clinical trial of the ATR-12 program for Netherton syndrome. Additionally, Azitra has initiated a Phase 1/2 clinical trial for the ATR-04 program, targeting EGFR inhibitor-associated dermal toxicity in adults. The design of the ATR-04 trial was previously presented at the 2025 American Society of Clinical Oncology Annual Meeting. Further updates and progress on these programs will be presented by Cofounder and Chief Operating Officer, Travis Whitfill, Ph.D., MPH, during a virtual presentation at the upcoming H.C. Wainwright 27th Annual Global Investment Conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY64956) on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2564637487","isCrawlerRequest":true}